MedTrace Logo

Inhaled Iloprost in Mild Asthma

NCT01209533 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2011-08-03

No results posted yet for this study

Summary

The purpose of the study is to determine if inhaled iloprost given four times daily can improve symptoms and lung function in adults with mild asthma.

Conditions

Interventions

DRUG

Iloprost

Inhaled iloprost 2.5 or 5 micrograms four times daily for 14 days

Sponsors & Collaborators

  • Actelion

    collaborator INDUSTRY

  • Vanderbilt University

    lead OTHER

Principal Investigators

  • James Sheller, M.D. · Vanderbilt University

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01209533 on ClinicalTrials.gov